Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRICLOS is an oral small-molecule solution in pre-launch development by Sanofi. The mechanism of action and indications are not yet disclosed publicly. Patient population and therapeutic area remain undetermined.
Pre-Launch
Pre-launch stage offers opportunity to build brand infrastructure and commercial strategy from inception; team size likely small but expanding as approval approaches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Wound Healing and Bacterial Adherence With Triclosan-Coated Sutures After Mandibular Impacted Third Molar Surgery
Started Oct 2025
Career Relevance
TRICLOS pre-launch status offers entry-level and senior positions building commercial, medical, and regulatory infrastructure. Working on this product provides hands-on experience in drug launch preparation and early-stage brand development within Sanofi.
Brand Manager
Worked on TRICLOS at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.